Trial Profile
Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Lobeglitazone (Primary) ; Sitagliptin (Primary) ; Glimepiride/metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Triple3
- 02 Jan 2022 Status changed from active, no longer recruiting to completed.
- 29 Mar 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.
- 29 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 31 Dec 2021.